Amiodarone-induced pulmonary toxicity: Case study with syndrome analysis

Heart and Lung: Journal of Acute and Critical Care

Volumn 42, Issue 4, 2013, Pages 262-266

  Van Cott, Theodore E ^a   Yehle, Karen S ^a   DeCrane, Susan K ^a   Thorlton, Janet R ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; DIURETIC AGENT; SOTALOL;

ACUTE HEART INFARCTION; ADULT; AMIODARONE INDUCED PULMONARY TOXICITY; ARTICLE; BLOOD CLOT; CARDIOVERSION; CASE REPORT; CORONARY STENT; COUGHING; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LUNG INFILTRATE; LUNG TOXICITY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DYSPNEA; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED;

EID: 84880030645     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2013.05.004     Document Type: Article

References (46)

1. Punnam S., Goyal S., Kotaru V., Pachika A., Abela G., Thakur R. Amiodarone - a 'broad spectrum' antiarrhythmic drug. Cardiovasc Hematol Disord Drug Targets 2010, 10:73-81.
2. Ernawati D., Stafford L., Hughes J. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008, 66:82-87.
3. Dusman R., Stanton M., Miles W., et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990, 82:51-59.
4. Donaldson L., Grant I., Naysmith M., Thomas J. Acute amiodarone-induced lung toxicity. Intensive Care Med 1998, 24:626-630.
5. AHFS: Drug Information 2013, American Society of Health-System Pharmacists, Bethesda, MD. G.K. McEvoy (Ed.).
6. Adams P., Holt D., Storey G., Morley A., Callaghan J., Campbell R. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985, 72:1064-1075.
7. Halliwell W. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 1997, 25:53-60.
8. Bedrossian C., Warren C., Ohar J., Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol 1997, 1:47-56.
9. Papiris S., Triantafillidou C., Kolilekas L., Markoulaki D., Manali E. Amiodarone: review of pulmonary effects and toxicity. Drug Saf 2010, 33:539-558.
10. Kennedy J., Myers J., Plumb V., Fulmer J. Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations. Arch Intern Med 1987, 147:50-55.
11. Baritussio A., Marzini S., Agostini M., et al. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1189-L1199.
12. Kuruma T., Maruyama T., Harada M., et al. Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance. Int J Cardiol 2009, 134:224-230.
13. Reinhart P., Gairola C. Amiodarone-induced pulmonary toxicity in Fischer rats: release of tumor necrosis factor alpha and transforming growth factor beta by pulmonary alveolar macrophages. JToxicol Environ Health 1997, 52:353-365.
14. Bargout R., Jankov A., Uhal B., et al. Amiodarone induces apoptosis of human and rat alveolar epithelial cells invitro. Am J Physiol Lung Cell Mol Physiol 2000, 278:L1039-L1044.
15. Uhal B., Wang R., Laukka J., Zhuang J., Soledad-Conrad V., Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol 2003, 92:81-87.
16. Uhal B., Zhang H., Abdul-Hafez A., Shu R., Li X. Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1. Basic Clin Pharmacol Toxicol 2007, 100:59-66.
17. Reasor M., Kacew S. An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Exp Biol Med 1996, 212:297-304.
18. Hawthorne H., Wood M., Stambler B., Damiano R., Ellenbogen K. Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation?. Pacing Clin Electrophysiol 1993, 16:2241-2249.
19. Greenspon A., Kidwell G., Hurley W., Mannion J. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991, 84:III407-III415.
20. Van Mieghem W., Coolen L., Malysse I., Lacquet L., Deneffe G., Demedts M. Amiodarone and the development of ARDS after lung surgery. Chest 1994, 105:1642-1645.
21. Kay G., Epstein A., Kirklin J., Diethelm A., Graybar G., Plumb V. Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 1988, 62:490-492.
22. Taylor C., Hodgkinson J., Hobbs F. Rhythm control agents and adverse events in patients with atrial fibrillation. Int J Clin Pract 2010, 64:1069-1075.
23. Vigreux P., Lemozit J., Delay M., Bernadet P., Montastruc J. Antiarrhythmic drug-induced side effects: a prospective survey of 300 patients. Therapie 1995, 50:413-418.
24. Bongard V., Marc D., Philippe V., Jean-Louis M., Maryse L. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006, 13:315-319.
25. Olshansky B., Sami M., Rubin A., et al. Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 2005, 95:404-405.
26. Magro S., Lawrence E., Wheeler S., Krafchek J., Lin H., Wyndham C. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. JAm Coll Cardiol 1988, 12:781-788.
27. Le Heuzey J., De Ferrari G., Radzik D., Santini M., Zhu J., Davy J. Ashort-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. JCardiovasc Electrophysiol 2010, 21:597-605.
28. Vorperian V., Havighurst T., Miller S., January C. Adverse effects of low dose amiodarone: a meta-analysis. JAm Coll Cardiol 1997, 30:791-798.
29. Jackevicius C., Tom A., Essebag V., et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol 2011, 108:705-710.
30. Yamada Y., Shiga T., Matsuda N., Hagiwara N., Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007, 71:1610-1616.
31. Ott M., Khoor A., Leventhal J., Paterick T., Burger C. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003, 123:646-651.
32. Camus P., Martin W., Rosenow E. Amiodarone pulmonary toxicity. Clin Chest Med 2004, 25:65-75.
33. Goldschlager N., Epstein A., Naccarelli G., et al. Apractical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007, 4:1250-1259.
34. Fuster V., Rydén L., Yancy C., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:e269-e367.
35. Zipes D., Camm A., Zamorano J., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). JAm Coll Cardiol 2006, 48:e247-e346.
36. Epstein A., DiMarco J., Yancy C., et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. JAm Coll Cardiol 2008, 51(21):e1-e62.
37. Chendrasekhar A., Barke R., Druck P. Recurrent amiodarone pulmonary toxicity. South Med J 1996, 89:85-86.
38. Marchlinski F., Gansler T., Waxman H., Josephson M. Amiodarone pulmonary toxicity. Ann Intern Med 1982, 97:839-845.
39. Kudenchuk P., Pierson D., Greene H., Graham E., Sears G., Trobaugh G. Prospective evaluation of amiodarone pulmonary toxicity. Chest 1984, 86:541-548.
40. Morera J., Vidal R., Morell F., Ruiz J., Bernadó L., Laporte J. Amiodarone and pulmonary fibrosis. Eur J Clin Pharmacol 1983, 24:591-593.
41. Kharabsheh S., Abendroth C., Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002, 89:896-898.
42. Burgess C., Blaikie A., Ingham T., Robinson G., Narasimhan S. Monitoring the use of amiodarone: compliance with guidelines. Intern Med J 2006, 36:289-293.
43. Snider M., Kalbfleisch S., Carnes C. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Clin Ther 2009, 31:1209-1218.
44. Wegener F., Ehrlich J., Hohnloser S. Dronedarone: an emerging agent withrhythm- and rate-controlling effects. JCardiovasc Electrophysiol 2006, 17:S17-S20.
45. Connolly S., Camm A., Halperin J., et al. Dronedarone in high-risk permanent atrial fibrillation. NEngl J Med 2011, 365:2268-2276.
46. U.S. Food and Drug Administration. 2011. FDA Drug Safety Communication: Review Update of Multaq (Dronedarone) and Increased Risk of Death and Serious Cardiovascular Adverse Events. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm283933.htm.